Abbott Laboratories (ABT) Cash from Investing Activities (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Cash from Investing Activities data on file, last reported at -$20.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 4224.26% year-over-year to -$20.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$22.3 billion (down 834.79% YoY), and the FY2025 full-year result was -$2.4 billion, down 3.59% from the prior year.
• Cash from Investing Activities declined to -$20.3 billion in Q1 2026, from -$913.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of -$264.0 million in Q2 2022 to a low of -$20.3 billion in Q1 2026.
• A 5-year average of -$1.8 billion and a median of -$582.0 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities jumped 62.65% in 2024 and slumped 4224.26% in 2026, its largest moves.
• Tracing ABT's Cash from Investing Activities over 5 years: stood at -$632.0 million in 2022, then slumped by 30.38% to -$824.0 million in 2023, then slipped by 5.1% to -$866.0 million in 2024, then dropped by 5.43% to -$913.0 million in 2025, then sank by 2126.07% to -$20.3 billion in 2026.
• Business Quant data shows ABT's Cash from Investing Activities at -$20.3 billion in Q1 2026, -$913.0 million in Q4 2025, and -$457.0 million in Q3 2025.